A. Schavgoulidze

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations

M. Mohty, M. Samur, H. Avet-Loiseau, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

O. Decaux, M. Mohty, P. Moreau, 2022, Haematologica.

Multiple Myeloma: Heterogeneous in Every Way

H. Avet-Loiseau, J. Corre, A. Perrot, 2021, Cancers.

Risk and Response-Adapted Treatment in Multiple Myeloma

H. Avet-Loiseau, J. Corre, A. Perrot, 2020, Cancers.

Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature.

M. Mohty, H. Avet-Loiseau, M. Macro, 2022, Blood.

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.

M. Mohty, H. Avet-Loiseau, M. Macro, 2022, Blood.

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

O. Decaux, M. Mohty, P. Moreau, 2022, Haematologica.

The Discriminatory Ability of the R-ISS Is Equivalent to the ISS in a Large Cohort of Newly Diagnosed Multiple Myeloma (NDMM) Patients

H. Avet-Loiseau, J. Corre, A. Perrot, 2020 .